Translational Genomics Research Institute (TGen) will head an international Dream Team of nearly two dozen researchers in the United States and United Kingdom that will focus on doubling the survival of patients with pancreatic cancer.

Dr. Daniel D. Von Hoff — TGen’s physician-in-chief and distinguished professor, chief scientific officer at HonorHealth Research Institute, and professor of medicine at Mayo Clinic — will lead the Stand Up To Cancer (SU2C) team. HonorHealth Research Institute will be the only clinical trial site in Arizona.

This is TGen’s second SU2C Dream Team focusing on pancreatic cancer with a third investigating new melanoma treatments. The American Association for Cancer Research is SU2C’s scientific partner and will administer the $12 million research grant over three years.